PuSH - Publikationsserver des Helmholtz Zentrums München

Zhou, X.D.* ; Jeong, S.* ; Chen, Q.F.* ; Targher, G.* ; Byrne, C.D.* ; Chew, N.W.S.* ; Younossi, Z.M.* ; Lip, G.Y.H.* ; Tilg, H.* ; George, J.* ; Stefan, N. ; Sperling, L.S.* ; Luu, H.N.* ; Fudim, M.* ; Loomba, R.* ; Zheng, M.H.*

Heart–liver co-management in MASLD: Expert perspectives and recommendations from a multidisciplinary cardiometabolic framework.

Nat. Rev. Gastroenterol. Hepatol., DOI: 10.1038/s41575-026-01255-z (2026)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is recognized as a systemic metabolic disorder with marked cardiovascular implications, as cardiovascular disease is a leading cause of death. Despite non-invasive diagnostic tests, such as the fibrosis-4 index and vibration-controlled transient elastography, and the availability of resmetirom and emerging pharmacotherapies with dual liver and cardiovascular benefits (for example, glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors), substantial gaps in coordinated clinical management remain. MASLD is often under-recognized in cardiology, and the cardiovascular risk associated with MASLD is similarly under-appreciated in hepatology practice, resulting in fragmented care and a lack of integrated management pathways. This discrepancy leads to missed opportunities for early intervention and suboptimal outcomes in the progression of both hepatic and cardiovascular diseases. To address these gaps, a more collaborative, multidisciplinary approach is needed, integrating early screening, risk stratification and coordinated management across specialities. In this Expert Recommendation, we outline key considerations for heart–liver co-management in MASLD, propose practical strategies for screening and risk stratification, and discuss pathways to implement coordinated multidisciplinary care in clinical practice within a structured metabolic care framework.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Glp-1 Receptor Agonists; Cardiovascular-disease; Global Epidemiology; Sglt2 Inhibitors; Dpp-4 Inhibitors; Risk; Association; Diagnosis; Failure; Trial
ISSN (print) / ISBN 1759-5045
e-ISSN 1759-5053
Zeitschrift Nature Reviews - Gastroenterology & Hepatology
Verlag Nature Publishing Group
Verlagsort Heidelberger Platz 3, Berlin, 14197, Germany
Begutachtungsstatus Peer reviewed
Institut(e) Institute for Diabetes Research and Metabolic Diseases (IDM)